Aravax: Funding, Investors & Team (Sep 2026)
Aravax is an early stage biotechnology company focused on developing the first safe and rapidly effective treatment for peanut allergy. The company is using their proprietary technology to reset the immune system to tolerate peanut without evoking allergic reactions during treatment. Aravax was founded in May 2015 through acquisition of intellectual property developed by Alfred Health and Monash University. Aravax has its headquarters in Melbourne, Australia.
Aravax has raised $20.0M across 1 funding round on record, the most recent a Series B of $20.0M announced in Dec 2022.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Aravax Company Profile and Key Stats
Latest funding round on record: Dec 2022.
Aravax Funding Rounds
Aravax Founders and Leadership Team
Contact details for the Aravax team: 1 of 1 has an email address on file.
Start 14-day free trial →Aravax Funding Compared to Other Biotechnology Startups
Aravax's latest round of $20.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Aravax in Biotechnology and Melbourne
Companies Similar to Aravax
AdvanCell is a company that focuses on developing innovative cancer treatments using alpha-emitting isotopes…
The objective of Fluent is to seamlessly integrate humans with AI, improving interaction and communication…
Mesoblast is a developer of biologic products for the broad field of regenerative medicine. Mesoblast's…
Microba Life Sciences Ltd. provides consumers, doctors, and researchers with gut microbiome testing services…
Algenie was founded on a simple realization: algae has the potential to save the earth, but only if it is…
Paradigm Pharmaceuticals is a global biopharmaceutical company driven to discover, develop, and deliver…
Imugene is a publicly-listed biotechnology company with operations in America and Europe,
BiomeBank’s mission is to treat and prevent disease by restoring gut microbial ecology
Telix Pharmaceuticals Ltd is a clinical-stage biotechnology company engaged in developing and commercializing…
Cauldron Ferm is a technique that speeds up the production of precision fermented prototypes to commercial…
HydGene Renewables is developing a biotechnology platform that produces on-site green hydrogen from waste…
Swan Genomics is focused on commercialising an innovative new approach to DNA sequencing to deliver more…
Aravax Funding FAQs
What does Aravax do?
Aravax is an early stage biotechnology company focused on developing the first safe and rapidly effective treatment for peanut allergy. The company is using their proprietary technology to reset the immune system to tolerate peanut without evoking allergic reactions during treatment. Aravax was founded in May 2015 through acquisition of intellectual property developed by Alfred Health and Monash University. Aravax has its headquarters in Melbourne, Australia.
How much funding has Aravax raised?
Aravax has raised $20.0M across 1 round on record. The most recent is a Series B of $20.0M announced in Dec 2022.
When did Aravax last raise funding?
Aravax's most recent funding round on record is a Series B of $20.0M, announced in Dec 2022.
Who founded Aravax?
FundedIQ lists Sara Prickett (Founder) at Aravax.
Where is Aravax headquartered?
Aravax is based in Melbourne, Victoria, Australia.
How many employees does Aravax have?
Aravax is in the 11-50 employee band.
How does Aravax's funding compare to other Biotechnology startups?
Aravax's latest round of $20.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Aravax Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Aravax is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.